<table>
<thead>
<tr>
<th><strong>AD NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADB243181</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NEW LIMITATION CHANGE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TO</strong></td>
</tr>
<tr>
<td>Approved for public release, distribution unlimited</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>FROM</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution authorized to U.S. Gov’t. agencies only; Proprietary Info.; Oct 98. Other requests shall be referred to US Army Medical Research and Materiel Command, Fort Detrick, MD 21702-5012.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>AUTHORITY</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>USAMRMC ltr dtd 4 Jan 2000</td>
</tr>
</tbody>
</table>

**THIS PAGE IS UNCLASSIFIED**
GRANT NUMBER DAMD17-96-1-6205

TITLE: Signaling Activity and Prognostic Significance of Variant Forms of p185HER-2/neu in Breast Cancer

PRINCIPAL INVESTIGATOR: Gail M. Clinton, Ph.D.

CONTRACTING ORGANIZATION: Oregon Health Sciences University
Portland, Oregon 97201-3098

REPORT DATE: October 1998

TYPE OF REPORT: Final

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Oct 98). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-96-1-6205
Organization: Oregon Health Sciences University
Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure, or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure, or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

[Signature]

[Date]
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

NA In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature]

PI - Signature

Date
**Title and Subtitle**

Signaling Activity and Prognostic Significance of Variant Forms of p185HER-2/neu in Breast Cancer

**Authors**

Gail M. Clinton, Ph.D.

**Performing Organization**

Oregon Health Sciences University
Portland, Oregon 97201-3098

**Funding Numbers**

DAMD17-96-1-6205

**Abstract**

We investigated an N-terminally truncated HER-2/neu product of 95 kDa, for its relationship to shedding of the extracellular domain (ECD) of p185HER-2 and for its association with prognostic factors in human breast cancer. P95 had in vitro kinase activity indicating it is active as a signaling protein and its levels correlated with the ECD shed from different cells under varied conditions. Cancer tissues were analyzed by western blotting and scored for p95 and for p185HER-2/neu expression. Of 161 breast cancer tissues, 22.4% expressed p95, 21.7% overexpressed p185, and 14.3% were both p95 positive and overexpressed p185. A higher proportion of node positive patients (23 of 78) than node negative patients (9 of 63) expressed p95 in all tumors combined (P=.032). In the group that overexpressed p185, those that contained p95 were associated with node positive patients (15 of 21), whereas those that were p95 negative were associated with node negative patients (8 of 11) (P=.017). Our findings show that breast cancers, which express the HER-2/neu oncogene, are heterogeneous with respect to HER-2/neu protein products. P95HER-2/neu appears to distinguish tumors that have metastasized to the lymph nodes from those in node negative patients.
<table>
<thead>
<tr>
<th>TABLE OF CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Documentation page</td>
<td>1</td>
</tr>
<tr>
<td>Table of contents</td>
<td>2</td>
</tr>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Conclusions</td>
<td>10</td>
</tr>
<tr>
<td>References</td>
<td>11</td>
</tr>
<tr>
<td>Appendicies</td>
<td>16</td>
</tr>
</tbody>
</table>
INTRODUCTION

Subject and background: The HER-2/neu gene encodes a receptor-like tyrosine kinase (RTK) which is a member of the epidermal growth factor receptor family (1). Overexpression of HER-2/neu has been observed in tumors arising at many sites including lung (2), colon (3), prostate (4), ovary, and breast (5). In human breast cancer, where HER-2/neu involvement has been extensively studied, overexpression occurs in 15-30% of the cases (see 6) and predicts for significantly lower survival rate and shorter time to relapse in patients with lymph node positive disease (5-8). The significance of HER-2/neu in node negative patients is controversial and so far its clinical utility as a prognostic indicator is limited (8,9). Various approaches are being taken toward HER-2/neu targeted therapeutics many of which are based on antibodies specific to the extracellular domain (ECD) of the transmembrane protein, which either down regulate receptor function or target recombinant toxins with the goal of specifically killing HER-2/neu expressing tumor cells (8,9,10).

In addition to the full length transmembrane product, p185, of the HER-2/neu gene, a truncated product corresponding to the extracellular domain (ECD) is released from breast carcinoma cells in culture by regulated proteolysis (11-13), and is also produced from an alternative transcript (14). HER-2/neu ECD is elevated in the serum of patients with breast (15), ovarian (16), and prostate cancer (17). Several studies of breast cancers estimate that 6% or less of early stage, about 25% of patients with metastatic and locally advanced disease, and greater than 50% of patients with recurrent metastatic disease have elevated serum ECD (see 18). Elevated ECD in serum is associated with overexpression of HER-2/neu in tumor tissue and also reflects tumor load (19-20). Soluble HER-2/neu is a marker of metastatic disease and may predict recurrence (19), shortened survival (20-23), and response to antiestrrogen therapy in advanced stage patients (24,25). Serum ECD has also been reported to neutralize the activity of anti HER-2/neu antibodies targeted to the ECD (26,27) possibly allowing escape of HER-2-rich tumors from immunological control.

Proteolytic release of the ECD is expected to create an N-terminally truncated, membrane-associated fragment with kinase activity. Cellular fragments created by ectodomain shedding have been described for the colony stimulating factor receptor (CSF-1R) (28), the TrkA neurotrophin receptor (29), Axl receptor (30), and HER-4 (31), while a truncated cellular product of HER-2/neu shedding has not yet been identified. The truncated CSF-1R was found to have in vitro kinase activity (28), and the cytoplasmic HER-4, induced by phorbol ester tumor promoters, had little or no kinase activity (31) while a truncated HER-4 found in cells treated with a proteosome inhibitors was an active kinase (32).

Several lines of evidence indicate that the ECD of full length transmembrane receptors exerts a negative regulatory constraint on their signaling activity. Engineered deletion of a region of the HER-2 ECD was found to enhance its oncogenic potency (33-36). This has been
illustrated by engineered removal of the ECD from the epidermal growth factor (EGF) receptor and by the oncogenic potency of viral encoded v-erbB, v-kit, and v-ros, that are missing regions of the ECD found in their normal cellular counterparts (37). Naturally occurring mutant EGF receptors with N-terminal truncations have been identified in several human carcinomas (38) and have constitutive signaling activity and enhanced oncogenic transforming activity in cell culture and animal models (39,40).

Purpose and scope: The purpose of the project was to investigate the signaling activity and prognostic significance of variant forms of p185HER-2 in breast cancer. In particular, we sought to investigate the signaling activity and possible prognostic significance of the N-terminally truncated HER-2 product, hypothesized to be the cytoplasmic tail of shedding.

BODY

Following is a revised SOW submitted to the Army last year: We have listed the task as originally proposed and then described the modifications and results that were obtained. This revised SOW was approved. All figures are in the manuscript in the appendix.

Task 1 Months 1-12: Further characterizations of selected samples and their variant forms will be conducted. Originally this was to be conducted on cancer tissues in a 3 month period. However additional time was needed to further characterize the HER-2/neu products in cultured cells first before going to the cancer tissues. Reviewers of our manuscript requested additional data on the structure and function of the p95 kinase domain (originally called p80) in cultured cells, its correlation with shedding of the ECD, evidence of its signalling activity, and additional evidence that it was created by proteolytic processing in intact cells.

SIGNALLING ACTIVITY OF P95

N-terminally truncated p95 has kinase activity. HER-2 transfected cells, 17-3-1, were extracted, resolved in gels, and immunoblotted with antibodies against the C-terminus of the HER-2/neu product [anti-neu(C)]. Two major protein products were detected in cell extracts; the full length p185 HER-2/neu and a truncated protein of about 95 kDa (Fig. 1, lane 1). Extracts were immunoprecipitated and the 95kDa protein as well as p185HER-2/neu were phosphorylated in the immune complex with (γ-32P)ATP (Fig. 1, lane 2). A monoclonal antibody specific for the N-terminal region of p185HER-2/neu [anti-neu(N)] did not immunoprecipitate p95 indicating that the N-terminal region was missing (lane 3). To examine whether p95 had self-phosphorylating activity or was a substrate of the full length receptor tyrosine kinase, p185 was first removed from the cell lysate with anti-neu(N), and then p95 was immunoprecipitated with anti-neu(C). P95 was phosphorylated when p185 levels were greatly depleted (Fig. 1 lane 4) indicating that it has kinase activity.

P95 kinase activity is in human breast carcinoma cells but not in nontumorigenic breast epithelial cells. The breast carcinoma cell line, BT474, known to release soluble ECD (11) also contained two autophosphorylated HER-2/neu products, p185 and p95, which were at elevated levels compared to the nontumorigenic breast epithelial cell line HBL-100 (Fig. 2). It
was possible that p95 could not be detected in the small amount of HBL-100 cells, since they express low levels of HER-2 (43). To compensate for different levels of HER-2/neu expression (43), the amounts of extract from HBL-100, human mammary epithelial cells, (HMEC), and three breast carcinoma cell lines were adjusted and proteins were phosphorylated with (γ-32P) ATP. P95 was detected in the low (MDA-MB-453) and high (BT474 and SKBR3) HER-2/neu expressing breast carcinoma cells, but not in the HBL-10 nor HMEC cells, despite a robust signal from the HER-2/neu receptor which migrated as a slightly smaller protein in the breast epithelial cells (Fig. 2).

**P95 is tyrosine phosphorylated and in the membrane fraction from BT474 cells.**

Tyrosine phosphorylation of tyrosine kinase receptors indicates their activation in signaling (9,10). The tyrosine phosphorylation of p95, and its subcellular location were examined by fractionation of BT474 cell extracts into a soluble fraction and a particulate fraction which were immunoprecipitated with anti-neu(C) and then subjected to western blot analysis using monoclonal antibodies against phosphotyrosine. Figure 3 illustrates that tyrosine phosphorylated p95 fractionated with p185 in the particulate fraction which contains the plasma membranes. P95 was further shown to be tyrosine phosphorylated by first immunoprecipitating with anti-phosphotyrosine antibodies and then probing the western blot with anti-neu(C).

**P95 CORRELATES WITH SHEDDING OF THE ECD**

*P95 correlates with shedding of the ECD from different cells treated with TPA and chloroquine.* To examine the relationship of p95 to soluble ECD, their levels were compared in different cells under varied conditions. The basal levels of ECD and cellular p95HER-2/neu were first examined in two cell lines that overexpress HER-2/neu, BT474 and the ovarian carcinoma cell line SKOV-3, which was previously reported to produce low levels of ECD (13). The amount of p95 relative to p185 and to cell protein was greatly elevated in BT474 cells and correspondingly, the ECD in the extracellular medium from BT474 cells, detected with anti-neu(N), was enhanced by greater than 10 fold compared to the SKOV3 cells (Fig.4).

Shedding of several membrane proteins is rapidly and transiently induced by phorbol ester tumor promoters (44,45). While short term treatment with tumor promoters does not induce HER-2 shedding (31), chronic administration of the phorbol ester TPA synergizes with chloroquine to stimulate release of soluble HER-2 (Christianson, Lin, and Clinton, unpublished observations). To determine whether p95 and ECD were coordinately regulated, TPA (500 nM) and chloroquine (50 μM) or the control vehicle were added to the culture media of BT474 and SKOV3 cells. At 24 hrs, the ECD levels in the extracellular media and p95 levels in the cell extract were analyzed. Soluble ECD was elevated several fold in the conditioned medium from stimulated BT474 cells and SKOV3 cells, while p95 was upregulated about three-fold in BT474 cells (Fig.4). Overexposure of the immunoblot revealed that p95 in SKOV3 cell extracts was also stimulated about three-fold by TPA and chloroquine (data not shown).

*A metalloprotease inhibitor depresses levels of p95 and ECD from BT474 cells.* The shedding of diverse transmembrane proteins has been found to be inhibited by hydroxamic
acid-based compounds, which are potent metalloproteinase inhibitors (46-48). We therefore tested the effects of different concentrations of the hydroxamic acid, TAPI (47) on shedding of HER-2/neu ECD and on cell levels of p95. TAPI at 0 to 40 μM was added to cultured BT474 cells for 24 hrs, the ECD in concentrated conditioned media was analyzed by immunoblotting with anti-neu(N), and p95 and p185 were examined in cell extracts using anti-neu(C). The results in Figure 5 show that production of ECD was partially inhibited at 1μM TAPI and maximally inhibited by 10 μM TAPI. A residual amount of about 10% of the ECD resisted inhibition by 40 μM TAPI. The level of truncated p95 in the cytoplasm was also inhibited by TAPI, with little or no effect at 1 μM and maximal inhibition at 10 μM (Fig.5). In three separate experiments, 1μM TAPI inhibited ECD and p95 levels by 50% or less, and in all cases, maximum inhibition was achieved by 10 μM of TAPI. No change in p185HER-2/neu levels could be detected in cells treated with TAPI or when shedding was stimulated by TPA and chloroquine (Fig.4) probably because proteolytic processing of p185 is constitutive and limited with about 20% converted into soluble HER-2/neu in 2 hrs (13).

In vitro kinase activity of p95 in breast cancer tissue. As originally proposed, we characterized tissue samples by immunoprecipitations to detect autophosphorylation activity of HER-2/neu variant products. We subsequently gave up this approach because we could not extract products that retained their enzyme activity from available tumor tissues.

**Task 2:** Months 4-7: *Additional characterizations providing new information on these samples.*

This task was modified and basically incorporated into Task 1. Immunohistochemical examination of tissue samples did not reveal distinct subcellular locations of HER-2/neu reactive proteins when the samples contained large amounts of the kinase domain. Further, the task of coimmunoprecipitations with active signaling molecules such as phospholipase C could not be completed since prohibitively large amounts of tissue were required to observe the targeted proteins by the technique of coimmunoprecipitation.

**Task 3** Months 8-16. This task involved developing techniques to analyze and quantitate HER-2 proteins in breast cancer tissues.

*Analysis of p95HER-2 in breast cancer tissue.* To establish a standard for quantitation of HER-2/neu variant forms in western blots of breast cancer tissues, we first analyzed a variety of tumor tissue to define a group that overexpressed HER-2/neu using an ELISA immunoassay approach. Aliquots of membrane-rich fractions prepared from breast cancer tissue were assayed using the Triton Diagnostics c-erbB-2 Tissue Extract EIA kit (Ciba Corning). This assay employed two monoclonal antibodies against the HER-2/neu ECD. The HER-2/neu units/mg protein in the specimens were calculated from a calibration curve generated by plotting the HER-2/neu concentration of the calibration standards versus the absorbance obtained from the immunoassay. To define the samples that overexpressed p185HER-2/neu, specimens with HER-2 immunoassay values that were considered HER-2/neu-rich (400 units or greater) compared to samples with low HER-2/neu levels (less than 400 units) were characterized for their p185 signal. Once several samples that overexpressed HER-2/neu were defined based on ELISA, these samples were compared with control standard cell extracts to
define an internal standard to be used for the entire study to analyze multiple tumor tissue. We chose the control cells, 17-3-1, which are transfected and overexpress HER-2/neu. Comparisons of the control cell extracts with tumor tissue found to overexpress HER-2/neu by ELISA revealed that a signal for p185 that was greater than or equal to the signal from the control cell extracts defined the group that overexpressed HER-2/neu. Those samples with a p185 signal that could be detected by 1 min exposure of the membrane to film and that was equal to or greater than the p185 level found in 3 μg of 17-3-1 cells, as revealed by laser densitometric analysis of the film, were scored as highly positive. Twenty μg of protein from the membrane fraction prepared from each tumor sample were resolved under denaturing and reducing conditions by SDS-PAGE in 10% gels. Each gel also contained 3 μg of protein from extracts of 17-3-1 cells to mark the migration of p185 and p95 and to provide a standard for the entire study. Proteins were electrotransferred onto membranes as described above, which were incubated with anti-neu(C) diluted 1:10,000 in TBS-Tween at 4°C overnight with shaking and then incubated with a 1:10,000 dilution of goat anti-rabbit HRP conjugated antibody (Bio-Rad) for 40 min at room temperature. To develop the blot, the membranes were incubated with chemiluminescent reagent and exposed to film for 1, 5, 20, and 120 min.. In the samples that had detectable p95, its level ranged from 10% to 100% of p185. Specimens were scored as positive if p95 was detected at a 10% or greater proportion of p185 by 2 hrs of exposure of the membrane to film. Because of the high titer of the primary antibody, anti-neu(C), there were rarely any background bands even when the immunoblots were exposed to film for 2 hrs. It took additional time to develop and characterize the ELISA test.

**Task 4 months 16-22:** Breast cancer samples (about 600) will be pulverized, aliquoted, extracted and protein amounts determined. This task was similar except that the time frame was longer than expected and fewer breast cancers were analyzed. This step took longer because we had to conduct additional fractionation steps on the breast cancer tissues. These additional steps were required because of the contamination with extracellular matrix components which diluted the breast cancer tissues to be analyzed. These fractionations required examining HER-2/neu proteins at each step of the procedure to define the fractionation properties. In addition, fewer samples were analyzed than originally expected.

**p95HER-2 IS ASSOCIATED WITH LYMPH NODE METASTASIS IN BREAST CANCER.**

*Detection of p185 and p95 HER-2/neu in breast cancer tissue.* Tumor tissues were homogenized, fractionated, and examined for HER-2/neu proteins by western analysis. The membrane-enriched but not the soluble fraction (data not shown) from some tumor tissues contained the full length product, p185, and the truncated p95HER-2/neu protein that comigrated with HER-2/neu proteins from the control 17-3-1 cells (Fig. 6). In addition, p95, along with p185, was detected in 2 of 8 ovarian cancer tissues (data not shown). Initial analyses of several breast cancer tissues revealed distinct expression patterns of p95 and p185. One group had no detectable p185 or p95 (see # 39 and 69, Fig. 6). A second category of specimens expressed both p185 and p95 (#60,53,04,22). An additional group contained p185
with relatively little or no p95 (#40,58,38,57,17,75). As observed in previous studies, some samples were p185-rich (#04,22,57,17,75). The samples that were characterized as highly positive for p185 were initially identified by immunoassay values of greater than 400 units (see Methods and legend to Fig. 6). The results of the western analysis suggested that the tumors were heterogeneous with respect to HER-2/neu protein products and that they could be subdivided based on the presence or absence of p95.

Western analysis of 161 breast cancer samples revealed that 22.4% were p95 positive. The p185 positive samples were further subdivided into highly positive or HER-2-rich specimens based on comparisons with HER-2/neu overexpressing samples identified by immunoassay and comparisons with the control 17-3-1 extract as described in Methods. The highly positive p185 samples represented 21.7% of the total. All samples that expressed p95 were also positive for p185, although 65% of p185 positive samples did not contain p95. Of the p95 positive samples, 63.9% were also highly positive for p185 and 36% had low p185 levels.

Relationship between p95 positive, p185 highly positive, and other prognostic factors. Of 78 node-positive breast cancer patients, a higher proportion expressed p95, than for the node negative patients (P=.032), while p185 rich samples had no significant association with node status (Table 1). Neither p95 positive nor p185 rich samples correlated significantly with other factors known to predict poor prognosis (49) including estrogen receptor and progesterone receptor negativity or tumor size of 3 cm or greater (Table 1).

Influence of p95 in the p185 highly positive group. We questioned why a similar percentage of node positive and node negative patients were p185-rich (24.4% versus 22.2%, Table 1), while p95 was associated with node positive patients, since 65.7% of the p185-rich samples contained p95. We therefore examined whether the presence or absence of p95 in the specimens that overexpressed p185HER-2/neu affected the relationship with lymph node status (Table 2). The p185 highly positive samples that contained p95 (n=21) had a significantly higher association with metastasis to the lymph nodes, while the p185 highly positive samples that were negative for p95 (n=11) were associated with lymph node negative patients (P=.017).
Table 1 Relationship between p95 positive, p185 highly positive, and other prognostic factorsa

<table>
<thead>
<tr>
<th>Factor</th>
<th>% p95</th>
<th>P value</th>
<th>% p185</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Node Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pos(78)</td>
<td>29.5</td>
<td>.032</td>
<td>24.4</td>
<td></td>
</tr>
<tr>
<td>Neg(63)</td>
<td>14.3</td>
<td></td>
<td>22.2</td>
<td></td>
</tr>
<tr>
<td>Tumor Size</td>
<td></td>
<td>NS</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>≥3cm(54)</td>
<td>27.8</td>
<td></td>
<td>22.2</td>
<td></td>
</tr>
<tr>
<td>&lt;3cm(79)</td>
<td>17.7</td>
<td>NS</td>
<td>21.5</td>
<td></td>
</tr>
<tr>
<td>ER</td>
<td></td>
<td>NS</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Neg(37)</td>
<td>32.0</td>
<td></td>
<td>29.7</td>
<td></td>
</tr>
<tr>
<td>Pos(117)</td>
<td>19.7</td>
<td>NS</td>
<td>17.9</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td></td>
<td>NS</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Neg(59)</td>
<td>23.7</td>
<td></td>
<td>20.3</td>
<td></td>
</tr>
<tr>
<td>Pos(95)</td>
<td>22.1</td>
<td></td>
<td>23.2</td>
<td></td>
</tr>
</tbody>
</table>

* 161 samples were examined by western analysis. See Methods for a description of patient material used and methods of analysis. Not all samples had information for the factors examined.

b NS = not significant.

Table 2 Relationship between p185 highly positive samples that are p95 negative versus p95 positive with node status.

<table>
<thead>
<tr>
<th>p185 highly positivea</th>
<th>p95 positive</th>
<th>p95 negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>node positive</td>
<td>71.4%b</td>
<td>27.3%</td>
</tr>
<tr>
<td>node negative</td>
<td>28.6%</td>
<td>72.7%</td>
</tr>
</tbody>
</table>

a The p185 highly positive group (n = 32) was divided into those that contained p95 (n = 21) and those that were p95 negative (n = 11).

b The samples that contained p95 had a significantly higher association with node positive patients (15 of 21), and those that were p95 negative correlated with node negative patients (8 of 11) (P = .017).
For task 4, we also proposed to examine the signaling activity and prognostic significance of the LBDp-100 variant thought to be an intracellular form of the HER-2 ECD. Our studies revealed that this product was difficult to analyze, since it required each sample to be run on an additional gel under nonreducing conditions for detection with the monoclonal antibody. Moreover, there was not a biological rationale to examine its role in breast cancer since this product should be secreted based on missing its transmembrane domain. Additional studies found that this product accumulated in the endoplasmic reticulum and was not fully processed. Therefore, our studies focused on the truncated kinase domain because of the strong biological rationale, and based on its association with shedding of the HER-2/neu extracellular domain from cultured cells.

Task 5 months 20-22. Films will be scanned, standard curves prepared, and variant forms will be quantitated. Patients subsets will be defined based on patterns of variant expression. This task remained the same except was moved to a later period in the funding cycle corresponding to the added time required to characterize the variant forms and to fractionate and analyze tumor tissues. This task was accomplished as described above.

Task 6 months 20-24: Patients subgroups will be statistically correlated with disease stage at surgery, histological subtype of tumor and pathologic factors. Originally this task included patient outcome. However, because of the added complexities described above, this task was refocused to correlated p185HER-2/neu and truncated kinase domain expression with pathologic factors including tumor size, hormone receptor status, lymph node involvement, and stage of the disease.

In summary. We found a significant correlation of the p95 kinase domain with lymph node metastasis. In regard to our original aims and statement of work, we had to modify the time frame and the procedures to be employed. In addition, to publish our results, it was necessary to conduct additional analyses that were not anticipated when the original SOM was developed. We were successful in the final outcome of identification of an additional marker based on a HER-2/neu variant form.

CONCLUSIONS

In conclusion, it has been difficult to understand why HER-2/neu overexpression occurs in tumor tissue from both node negative and positive patients, yet it is a strong prognostic marker only in node positive patients. Our findings indicate that p95 is preferentially found in HER-2/neu positive patients with lymph node involvement. It is possible that higher expression of p95 is a critical factor that helps explain the increased prognostic significance of HER-2/neu in node positive patients. It will be of interest and importance to examine the prognostic significance of p95 particularly in node negative patients.
REFERENCES


31. Vecchi, M., Baulida, J., and Carpenter, G. Selective cleavage of the heregulin receptor ErbB-4 by Protein kinase C activation. J. Biol. Chem., 271: 18989-18995,
1996.


42. McKenzie, S.J., Marks, P.J., Lam, T., Morgan, J., Panicali, D.L., Trimpe, K.L., and


APPENDICIES

See copy of manuscript

Contains proprietary information
Bibliography:

Publication

Abstract
DOD "Era of Hope" Breast Cancer Meeting. October, 1997


Personnel Receiving Pay

Mr. Russell Moser, Research Associate
Ms. Baoyu Lin, Research Associate
Lisa Butler, Laboratory Aid
NH₂-terminally Truncated HER-2/neu Protein: Relationship with Shedding of the Extracellular Domain and with Prognostic Factors in Breast Cancer

Tracy A. Christianson,1 Joni K. Doherty,2 Yuzhong J. Lin,3,3 Elizabeth E. Ramsey, Ron Holmes, Edward J. Keenan, and Gail M. Clifton4

Departments of Biochemistry and Molecular Biology (T. A. C., Y. J. L., G. M. C., J. K. D.), and Physiology and Pharmacology (E. E. R., R. H., E. J. K.), Oregon Health Sciences University, Portland, Oregon 97201

INTRODUCTION

We identified an NH₂-terminally truncated HER-2/neu product of M, 95,000 with in vitro kinase activity by Western blotting and immunoprecipitations using domain-specific antibodies. p55 levels correlated with the extracellular domains (ECD) shed from different cell lines under varied conditions. Both ECD and p95 were at ~20-fold lower levels in SKOV3 ovarian carcinoma cells, as compared to BT474 breast carcinoma cells. Both were stimulated by treatment of cells with the phorbol ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate and the lymosomotropic agent chloroquine. The hydroxamate inhibitor of metalloproteases, TAPI, suppressed both p55 and ECD in a dose-dependent fashion, with maximal inhibition at ~1 μM in BT474 cells. Cancer tissues were analyzed by Western blotting and scored for p95/HER-2 (neu) and for p185/HER-2 (neu) expression. Breast and ovarian cancer tissues were both found to express p95/HER-2 (neu) in addition to p185/HER-2 (neu). OX lung and breast cancer lines, 22.4% expressed p95, 21.7% overexpressed p185, and 14.3% were p55 positive and overexpressed p185. A higher proportion of node-positive patients (23 of 78) than node-negative patients (9 of 63) expressed p95 in all tumors combined (P = 0.003). In the group that overexpressed p185, those that contained p95 were associated with node-positive patients (15 of 31), whereas those that were p95 negative were associated with node-negative patients (8 of 13; P = 0.017). Neither p95- nor p185-rich patients significantly correlated with tumor size or with hormone receptor status in this study. Our findings show that breast cancers, which express the HER-2/neu oncogene, are heterogeneous with respect to HER-2/neu protein products. p95HER-2 (neu) appears to distinguish tumors that have metastasized to the lymph nodes from those in node-negative patients.

Received 3/7/98; accepted 9/1/98.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertised in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1Supported by National Cancer Institute Grant CA-71447 and Department of Defense Breast Cancer Research Program Grant DAMD 17-92-D-2024, J. K. D. is a postdoctoral fellow of the Department of Defense Breast Cancer Research Program.

2The first three authors contributed equally to this work.

3Present address: Cascade Biologics, Inc., 4475 Southwest Scholls Ferry Road, Portland, OR 97223.

4To whom requests for reprints should be addressed at Department of Biochemistry and Molecular Biology, Oregon Health Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97233.

The abbreviations used are: RTK, receptor tyrosine kinase; ECD, extracellular domain; EGF, epidermal growth factor; HER2, human mammary epithelial cell; TRL, triglyceride-rich lipoprotein; LDL, low density lipoprotein; ECD, extracellular domain; 12-O-tetradecanoylphorbol-13-acetate; TAPI, 9-(4-carboxybenzyl)aminoacridine; TAT, tetrapeptide

Ox/nK

N-5,0-L-[[2-(Hydroxyaspartylzinc)carbamy1]methyl]-4-methylpentanoic acid

Φ

2,4-

l-carnitine

4,5-

2-

l-alanine

5

Orig. Op. 1st disk, 2nd LP 6
OPERATOR: Session PROOF: AA's: Pe's: COMMENTS

ARTNO: 533881

Please return proofs within 24 hours by overnight mail.
were cultured from tissue obtained from reduction mammoplasty. Antipeptide antibody against the COOH terminus of p185HER-2/neu, anti-ner(C), has been described previously (41). Monoclonal antibody against the ECD of HER-2/neu was prepared as described (42) and was provided by Applied BioTechnology, Inc.

Cell Culture. 17-3-1 cells were cultured in DMEM supplemented with 5% fetal bovine serum containing 0.4 mg/ml gentamicin (G418; Life Technologies, Inc.). The human breast cancer cell line MDA-MB-231 was cultured in RPMI 1640 medium supplemented with 10% FBS and 10 μg/ml insulin. All other cell lines were grown in DMEM supplemented with 10% FBS and the antibiotic gentamicin at 0.5 μg/ml.

Immunoprecipitations and Immune Complex Kinase Assays. Freshly prepared cell lysates in TEBD buffer (50 mM Tris, 1.5 mM EDTA, 0.5 mM DTT, 10% glycerol (pH 7.5) with 1% aprotinin, 2 mM phenylmethylsulfonyl fluoride, and 2 mM sodium vanadate) containing 1% NP-40 were immunoprecipitated with antibody to HER-2/neu for 2 h with 20 μl of protein A-Sepharose (Pharmacia) and then washed twice with TEDG buffer (50 mM Tris, 1.5 mM EDTA, 0.5 mM DTT, 10% glycerol, and 2 mM sodium vanadate). Immune complexes were resolved on SDS-polyacrylamide gels and transferred to nitrocellulose (Trans-Blot; Bio-Rad) using a semidry transfer unit (Bio-Rad) at 15 V for 20 min. The nitrocellulose membranes were then incubated with the primary antibody (anti-neu(C), anti-ner(N)) and then with horseradish peroxidase-conjugated secondary antibody. The complexes were then visualized by chemiluminescent reagent (Pierce). The signal was quantified by laser densitometric analysis of the film, and the immune complexes were incubated with a 1:100 dilution of primary antibody in TEDG buffer containing 10% FBS and 10 μg/ml insulin. The human breast cancer cell line MDA-MB-231 was cultured in RPMI 1640 medium supplemented with 10% FBS and 10 μg/ml insulin. All other cell lines were grown in DMEM supplemented with 10% FBS and the antibiotic gentamicin at 0.5 μg/ml.

Western Blotting. Following SDS-PAGE, cell lysates or proteins from stage 1a, 1b, or 2b tumors were separated on SDS-polyacrylamide gels, electroblotted onto nitrocellulose, and stained with primary antibody (anti-neu(C), anti-ner(N)) to detect p185HER-2/neu and a truncated protein of Mr 95,000 (Fig. 1). The lipid layer was collected with a wooden spatula from the membrane fraction prepared from each tumor sample were resolved under denaturing and reducing conditions by SDS-PAGE in 10% gels. The expression of p185 was determined by Western analysis. The human breast cancer cell line MDA-MB-231 was cultured in RPMI 1640 medium supplemented with 10% FBS and 10 μg/ml insulin. All other cell lines were grown in DMEM supplemented with 10% FBS and the antibiotic gentamicin at 0.5 μg/ml.

Immunoprecipitations and Immune Complex Kinase Assays. Freshly prepared cell lysates in TEBD buffer (50 mM Tris, 1.5 mM EDTA, 0.5 mM DTT, 10% glycerol (pH 7.5) with 1% aprotinin, 2 mM phenylmethylsulfonyl fluoride, and 2 mM sodium vanadate) containing 1% NP-40 were immunoprecipitated with antibody to HER-2/neu for 2 h with 20 μl of protein A-Sepharose (Pharmacia) and then washed twice with TEDG buffer (50 mM Tris, 1.5 mM EDTA, 0.5 mM DTT, 10% glycerol, and 2 mM sodium vanadate). Immune complexes were resolved on SDS-polyacrylamide gels and transferred to nitrocellulose (Trans-Blot; Bio-Rad) using a semidry transfer unit (Bio-Rad) at 15 V for 20 min. The nitrocellulose membranes were then incubated with the primary antibody (anti-neu(C), anti-ner(N)) and then with horseradish peroxidase-conjugated secondary antibody. The complexes were then visualized by chemiluminescent reagent (Pierce). The signal was quantified by laser densitometric analysis of the film, and the immune complexes were incubated with a 1:100 dilution of primary antibody in TEDG buffer containing 10% FBS and 10 μg/ml insulin. The human breast cancer cell line MDA-MB-231 was cultured in RPMI 1640 medium supplemented with 10% FBS and 10 μg/ml insulin. All other cell lines were grown in DMEM supplemented with 10% FBS and the antibiotic gentamicin at 0.5 μg/ml.

Western Blotting. Following SDS-PAGE, cell lysates or proteins from stage 1a, 1b, or 2b tumors were separated on SDS-polyacrylamide gels, electroblotted onto nitrocellulose, and stained with primary antibody (anti-neu(C), anti-ner(N)) to detect p185HER-2/neu and a truncated protein of Mr 95,000 (Fig. 1). The lipid layer was collected with a wooden spatula from the membrane fraction prepared from each tumor sample were resolved under denaturing and reducing conditions by SDS-PAGE in 10% gels. The expression of p185 was determined by Western analysis. The human breast cancer cell line MDA-MB-231 was cultured in RPMI 1640 medium supplemented with 10% FBS and 10 μg/ml insulin. All other cell lines were grown in DMEM supplemented with 10% FBS and the antibiotic gentamicin at 0.5 μg/ml.

Identification of NH2-terminally truncated HER-2/neu protein with Kinase Activity. 3T3 cells transfected with HER-2/neu CDNA (p185HER-2/neu) release soluble ECD by proteolytic processing of p185HER-2/neu (12). To detect truncated cysteins products, we resolved 17-3-1 extracts in gels and immunoblotted with antibodies against the COOH terminus of the HER-2/neu product (anti-ner(C)). Two major protein products were detected in cell extracts: the full-length p185HER-2/neu and a truncated protein of Mr 95,000 (Fig. 1, Lane 1). Extracts were immunoprecipitated, and the M, 95,000 protein was visualized with anti-ner(N) as well as p185HER-2/neu were phosphorylated in the immune complex with [γ-32P]ATP (Fig. 1, Lane 2). A monoclonal antibody that was specific for the NH2-terminal region of p185HER-2/neu anti-
neu(N)) did not immunoprecipitate p95, indicating that the NH\_2-terminal region was missing (Lane 3). To examine whether p95 had self-phosphorylating activity or was a substrate of the full-length RTK, p185 was first removed from the cell lysate with anti-neu(N), and then p95 was immunoprecipitated with anti-neu(C). p95 was phosphorylated when p185 levels were greatly depleted (Fig. 1, Lane 4), indicating that it has kinase activity.

p95 Kinase Activity Is in Human Breast Carcinoma Cells but not in Nonmumorigenic Breast Epithelial Cells. The breast carcinoma cell line, BT-474, known to release soluble ECD (11) also contained two autophosphorylated HER-2/neu products, p185 and p95, which were at elevated levels compared to the nonmumorigenic breast epithelial cell line HBL-100 (Fig. 2). It was possible that p95 could not be detected in the small amount of HBL-100 cell lysates because they express low levels of HER-2 (43). To compensate for different levels of HER-2/neu expression (43), the amounts of extract from HBL-100, HMECs, and three breast carcinoma cell lines were adjusted, and proteins were phosphorylated with \textsuperscript{[\gamma\text{-}}\text{P}]ATP. p95 was detected in the low (MDA-MB-453) and high (BT-474 and SKBR3) HER-2/neu-expressing breast carcinoma cells but not in the HBL-100 nor HMEC cells, despite a robust signal from the HER-2/neu receptor, which migrated as a slightly smaller protein in the breast epithelial cells (Fig. 2).

To examine whether p95 and ECD were coordinately regulated, TPA (500 nm) and chloroquine (50 \muM) were added to cell cultures. The ECD levels in the conditioned media from BT-474 cells were elevated severalfold in the conditioned media and p95 levels in the cell extract were analyzed by Western blotting with anti-neu(C) monoclonal antibody at 1 \mug/ml. 10 \mug of cell proteins were analyzed by Western blotting using anti-neu(C). The results are representative of three replicate experiments.

p95 Is Tyrosine-phosphorylated and Is in the Membrane Fraction from BT-474 Cells. Tyrosine phosphorylation of tyrosine kinase receptors indicates their activation in signaling (9, 10). The tyrosine phosphorylation of p95 and its subcellular location were examined by fractionation of BT-474 cell extracts into a soluble fraction and a particulate fraction, which were immunoprecipitated with anti-neu(C) and then subjected to Western blot analysis using monoclonal antibodies against phosphotyrosine. Fig. 3 illustrates that tyrosine-phosphorylated p95 fractionated with p185 in the particulate fraction, which contains the plasma membranes. p95 was further shown to be tyrosine-phosphorylated by first immunoprecipitating with antiphosphotyrosine antibodies and then probing the Western blot with anti-neu(C) (data not shown).

p95 Corresponds to Levels of Soluble ECD Released from Different Cells. To examine the relationship of p95 to soluble ECD, their levels were compared in different cells under varied conditions. The basal levels of ECD and cellular p95HER-2/neu were first examined in two cell lines that overexpress HER-2/neu, BT-474 and the ovarian carcinoma cell line SKOV-3, which was previously reported to produce low levels of ECD (13). The amount of p95 relative to p185 and to cell protein was greatly elevated in BT-474 cells, and correspondingly, the ECD in the extracellular medium from BT-474 cells, detected with anti-neu(N), was enhanced by >10-fold compared to the SKOV3 cells (Fig. 4).

Shedding of several membrane proteins is rapidly and transiently induced by phorbol ester tumor promoters (44, 45). Although short-term treatment with tumor promoters does not induce HER-2 shedding (31), chronic administration of the phorbol ester TPA synergizes with chloroquine to stimulate release of soluble HER-2\textsuperscript{+}. To determine whether p95 and ECD were coordinately regulated, TPA (500 \muM) and chloroquine (50 \muM) or the control vehicle were added to the culture media of BT-474 and SKOV3 cells. At 24 h, the ECD levels in the extracellular media and p95 levels in the cell extract were analyzed. Soluble ECD was elevated severalfold in the conditioned media of BT-474.
medium from stimulated BT474 cells and SKOV3 cells, whereas p95 was up-regulated ~3-fold in BT474 cells (Fig. 4). Overexpression of the immunoblot revealed that p95 in SKOV3 cell extracts was also stimulated about 3-fold by TPA and chloroquine (data not shown).

A Metalloprotease Inhibitor Depresses Levels of p95 and ECD from BT474 Cells. The shedding of diverse transmembrane proteins has been found to be inhibited by hydroxamic acid-based compounds, which are potent metalloprotease inhibitors (46–48). We, therefore, tested the effects of different concentrations of the hydroxamic acid TAPI (47) on shedding of HER-2/neu ECD and on cell levels of p95. TAPI at 0–40 μM was added to cultured BT474 cells for 24 h, the ECD in concentrated conditioned media was analyzed by immunoblotting with anti-neu(N). Similar results were obtained when 5 μg of proteins from the conditioned media from each culture were analyzed. B. 30 μg of cell proteins were analyzed by Western blotting using anti-neu(C).

The samples that were characterized as highly positive for p185 were initially identified by immunoblot assay of >400 units (see "Materials and Methods" and Fig. 6 legend). The results of the Western analysis suggested that the tumors were heterogeneous with respect to HER-2/neu protein products and that they could be subdivided based on the presence or absence of p95. Western analysis of 161 breast cancer samples revealed that 22.4% were p95 positive. The p185-positive samples were further subdivided into highly positive or HER-2-rich specimens, based on comparisons with HER-2/neu-overexpressing samples, identified by immunoblot assay and comparisons with the control 17-3-1 extract, as described in "Materials and Methods." The highly positive p185 samples represented 21.7% of the total samples. All samples that expressed p95 were also positive for p185, although 65% of p185-positive samples did not contain p95. Of the p95-positive samples, 63.9% were also highly positive for p185, and 36% had low p185 levels. Relationship between p95-positive, Highly p185-positive, and Other Prognostic Factors. The proportion of 78 node-positive breast cancer patients expressing p95 was higher than the proportion of node-negative patients expressing p95 (P = 0.032); p185-rich samples had no significant association with node status (Table 1).

Neither p95-positive nor p185-rich samples correlated significantly with the amount of cell extract, were analyzed by Western blotting with anti-neu(N). Similar results were obtained when 5 μg of proteins from the conditioned media from each culture were analyzed. B. 30 μg of cell proteins were analyzed by Western blotting using anti-neu(C).
with other factors known to predict poor prognosis (49), including ER and PR negativity and tumor size of >3 cm (Table 1). Influence of p95 in the Highly p185-positive Group. We questioned whether a similar percentage of node-positive and node-negative patients were p185 rich (24.4% versus 22.2%, Table 1), whereas p95 was associated with node-positive patients (65.7% of the p185-rich samples contained p95). We, therefore, examined whether the presence or absence of p95 in the specimens that overexpressed p185HER-2/neu affected the relationship with lymph node status (Table 2). The highly p185-positive samples that contained p95 (n = 21) had a significantly higher association with metatasis to the lymph nodes, whereas the highly p185-positive samples that were negative for p95 (n = 11) were associated with lymph node-negative patients (P = 0.017).

**DISCUSSION**

We identified an NH2-terminally truncated HER-2/neu product of Mr ~95,000, which was detected by Western blotting and by immunoprecipitation with antipeptide antibodies against the COOH terminus but did not react with monoclonal antibodies against the NH2 terminus of p185HER-2/neu. p95 has kinase activity evidenced by its self-phosphorylation when p185 was cleared from the cell extract prior to immunoprecipitation with anti-neu(C) (Fig. 1). Several controls and extraction procedures were conducted to rule out that p95 was created by an in vitro degradation event. Cells extracted with protease inhibitors had only two major cytoplasmic HER-2/neu proteins, p95 and p185, with no indication of smaller degradation products. p95 levels were not affected by procedures that would eliminate samples, it may impact the amplitude of the kinase signal. Moreover, the HER-2/neu product of disproportionately low amount of p95 (Fig. 4). These observations indicate that production of p95 is regulated. The cells with variable levels of truncated HER-2/neu products may differ in the amount of the relevant protease activity or the protein substrate may have an altered conformation affecting its sensitivity to proteolytic cleavage.

p55HER-2/neu has properties that suggested a rationale for examining its association with prognostic factors in breast cancers. It has kinase activity, is tyrosine-phosphorylated, suggesting its activity in signaling, and is truncated from its NH2 terminus. Oncogenic signaling by HER-2/neu is known to depend on its level of kinase activity (33–35). Because p55 was at 100% of p185 in some breast cancer samples, it may impact the amplitude of the kinase signal. Moreover, an NH2-terminally truncated kinase domain such as p95 is expected to emit a constitutive signal by analogy to results with engineered deletions of the ECD from the HER-2/neu protein (32–36). Taken together, the mechanism for this stimulation was not examined, long-term exposure of cells to TPA has been found to enhance internalization of RTKs (50), whereas chloroquine, an agent that alters the pH in endosomes and lysosomes, may inhibit complete proteolytic breakdown or alter RTK trafficking (51). Finally, p95 and ECD were both inhibited by addition of the hydroxamate compound, TAPI, to intact cells, and both were maximally inhibited by ~10 μM TAPI (Fig. 5). The strong inhibition by TAPI indicates that most of the ECD and p95 in BT474 cells were generated by a metalloprotease (46, 47) and that this class of inhibitors may be effective in controlling shedding in breast cancer patients. Although p95 and p185 are modulated under several different conditions, changes in the p185 levels could not be detected. Unlike several transmembrane proteins that only shed when induced by TPA, proteolytic shedding of p185 occurs continually at a low basal level (11, 12), with only ~20% converted into soluble ECD in 2 h (13). The cell line HER-2/neu (MCF-7) described here was somewhat larger than the expected Mr 75,000–80,000 for the cytoplasmic remnant of the Mr ~105,000–110,000 ECD. p95 or the ECD might migrate anomalously in gels because the site of cleavage for ECD shedding is not known. Although our studies showed that the ECD and p95 are coordinately produced in culture by proteolytic activity that is sensitive to a metalloprotease inhibitor, it is not yet known whether p95 levels in breast tumors will be directly coupled to serum ECD. In some cases, ECD may be the product of an alternative transcript (14), or the metabolism of p95 may vary in different cells. Future studies aimed at testing cancer tissue and serum from the same patients will be required to evaluate whether serum ECD correlates with tissue p95 in vivo. A HER-2/neu product of the same size, Mr 95,000, in transfected 3T3 cells, cultured breast carcinoma cells, and ovarian cancer tissue suggests that a similar proteolytic processing event may occur in the different cells. However, p95 was not detected in all cells and tumor tissue that contain p185. Two nontumorigenic breast epithelial cell lines had no detectable p95 (Fig. 2). In addition, the SKOV3 ovarian carcinoma cells, which overexpress p185, had a disproportionately low amount of p95 (Fig. 4). These observations indicate that production of p95 is regulated. The cells with variable levels of truncated HER-2/neu products may differ in the amount of the relevant protease activity or the protein substrate may have an altered conformation affecting its sensitivity to proteolytic cleavage.

### Table 1 Relationship between p95-positive and highly p185-positive status and other prognostic factors

<table>
<thead>
<tr>
<th>Factor</th>
<th>% p95 positive</th>
<th>% p185 highly positive</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nodes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>29.3</td>
<td>24.4</td>
<td>NS</td>
</tr>
<tr>
<td>Negative</td>
<td>14.3</td>
<td>22.2</td>
<td>NS</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>≥3 (54)</td>
<td>27.8</td>
<td>22.1</td>
<td>NS</td>
</tr>
<tr>
<td>&lt;3 (79)</td>
<td>17.3</td>
<td>21.5</td>
<td>NS</td>
</tr>
<tr>
<td>ER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>32.0</td>
<td>29.7</td>
<td>NS</td>
</tr>
<tr>
<td>Negative</td>
<td>19.7</td>
<td>17.9</td>
<td>NS</td>
</tr>
<tr>
<td>PR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>23.7</td>
<td>20.3</td>
<td>NS</td>
</tr>
<tr>
<td>Negative</td>
<td>22.1</td>
<td>23.2</td>
<td></td>
</tr>
</tbody>
</table>

* 161 samples were examined by Western analysis. See "Materials and Methods" for a description of patient material used and methods of analysis. Not all samples had information for the factors examined.

* NS, not significant.

### Table 2 Relationship between highly p185-positive samples that are p95 negative versus p95 positive and node status

<table>
<thead>
<tr>
<th>Node status</th>
<th>p95 positive (n = 21)</th>
<th>p95 negative (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Node positive</td>
<td>71.9%</td>
<td>27.3%</td>
</tr>
<tr>
<td>Node negative</td>
<td>26.6%</td>
<td>72.7%</td>
</tr>
</tbody>
</table>

* The highly p95-positive group (n = 32) was divided into those that contained p95 (n = 21) and those that were p95 negative (n = 11).

* The samples that contained p95 had a significantly higher association with node-positive patients (15 of 21), and those that were p95 negative correlated with node-negative patients (8 of 11; P = 0.017).
together, these results suggest that p95 will elevate the kinase signal in some patients and could, thereby, be associated with more aggressive tumor growth. Although this was the biological rationale used in our study, p95 could also mark tumors that express a particular protease that is relevant to breast cancer pathology.

In this study, 161 breast cancer tissues were homogenized, fractionated, and analyzed by Western blotting, a technique required to distinguish p185 from the truncated cytoplasmic protein. A comprehensive study conducted by Tandon et al. (32) also used Western analysis of breast tissue extracts, but they evaluated only the full-length product, p185. In agreement with their results, we also found p185 expressed frequently in breast tumors, with a subpopulation of 21.7%, compared to their proportion of highly positive scores (16%). Western blot technique has been reported to be the most prone to dilutional artifacts introduced by extracellular matrix from stroma-rich cancers (29). For our study, homogenized tissue was fractionated into a membrane-rich fraction, from which relatively insoluble extracellular matrix proteins would tend to be eliminated.

One of the major findings of this study is that breast cancers, which express p95, were associated with receptor status. Importantly, the distinct products, p95 and p185, were differentially associated with node status. Although the group that overexpressed p185 did not associate with node status (Table 1), those that were p185-rich and contained p95 were significantly associated with lymph node metastasis (Table 2). This may help explain why several previous studies, which have attempted to show association with lymph node metastasis as based on assays of p185 protein overexpression or HER-2/neu gene amplification, have yielded inconsistent results (see Ref. 6). A biological explanation for our findings is that the loss of the ECD regulatory region from the p95 kinase combined with amplification p185 signal in primary breast tumor cells could promote their metastasis to the lymph nodes.

p95-positive or highly p185-positive samples did not correlate with other prognostic markers in this study, including tumor size or hormone receptor status. Although no consistent correlation with tumor size has been detected, other studies have reported association of HER-2/neu-positive patients with lymph node involvement.

HER-2/neu overexpression occurs in tumor tissue from both node-negative and node-positive patients, yet it is a strong prognostic marker only in node-positive tumors. There is an increased degree of differential expression of the HER-2/neu oncogene in human breast and ovarian cancers. (Science (Washington DC), 225: 177–182, 1984).


REFERENCES


MEMORANDUM FOR Administrator, Defense Technical Information Center, ATTN: DTIC-OCA, 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for the attached Grants. Request the limited distribution statements for Accession Document Numbers listed be changed to "Approved for public release; distribution unlimited." This report should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by email at Judy.Pawlus@amedd.army.mil.

FOR THE COMMANDER:

PHYLIS M. RINEHART
Deputy Chief of Staff for Information Management

Completed 1-13-00 en